Please login to the form below

Not currently logged in
Email:
Password:

Evrysdi

This page shows the latest Evrysdi news and features for those working in and with pharma, biotech and healthcare.

Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi

Roche scores FDA approval for SMA drug risdiplam, now named Evrysdi

Evrysdi becomes the third drug approved to treat the condition and is the first that can be administered orally. ... Roche has priced Evrysdi by patient weight, with a maximum cost of $340, 000 per year, which is much less than its competitors.

Latest news

More from news
Approximately 1 fully matching, plus 1 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health™

Syneos Health™ is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract...

Latest intelligence

Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...
Improve clinical trials through patient journey mapping
Could patient journey mapping be your solution to improving clinical study recruitment and retention? While awareness of clinical studies is low across the population, it’s not the only issue. It’s...

Infographics